CN110366427A - 一种预防和治疗病理性肾组织损伤的方法 - Google Patents

一种预防和治疗病理性肾组织损伤的方法 Download PDF

Info

Publication number
CN110366427A
CN110366427A CN201780078167.1A CN201780078167A CN110366427A CN 110366427 A CN110366427 A CN 110366427A CN 201780078167 A CN201780078167 A CN 201780078167A CN 110366427 A CN110366427 A CN 110366427A
Authority
CN
China
Prior art keywords
plasminogen
renal
subject
damage
kidney
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078167.1A
Other languages
English (en)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Talengen Institute of Life Sciences Co Ltd
Original Assignee
Talengen Institute of Life Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen Institute of Life Sciences Co Ltd filed Critical Talengen Institute of Life Sciences Co Ltd
Publication of CN110366427A publication Critical patent/CN110366427A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Abstract

一种预防和/或治疗受试者肾组织损伤的方法，包括给药受试者有效量的纤溶酶原，其中该受试者有肾组织损伤风险、怀疑有肾组织损伤、或罹患肾组织损伤。还提供了在用于预防和/或治疗受试者肾组织损伤及其相关病症的包含纤溶酶原的药物、药物组合物、制品、试剂盒。

Description

PCT国内申请，说明书已公开。

Claims (66)

  1. PCT国内申请，权利要求书已公开。
CN201780078167.1A 2016-12-15 2017-06-19 一种预防和治疗病理性肾组织损伤的方法 Pending CN110366427A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/110174 2016-12-15
CN2016110169 2016-12-15
CNPCT/CN2016/110169 2016-12-15
CN2016110174 2016-12-15
PCT/CN2017/089060 WO2018107700A1 (zh) 2016-12-15 2017-06-19 一种预防和治疗病理性肾组织损伤的方法

Publications (1)

Publication Number Publication Date
CN110366427A true CN110366427A (zh) 2019-10-22

Family

ID=62557856

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780078117.3A Pending CN110167582A (zh) 2016-12-15 2017-06-19 一种预防和治疗药物性肾损伤的方法
CN201780078167.1A Pending CN110366427A (zh) 2016-12-15 2017-06-19 一种预防和治疗病理性肾组织损伤的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201780078117.3A Pending CN110167582A (zh) 2016-12-15 2017-06-19 一种预防和治疗药物性肾损伤的方法

Country Status (7)

Country Link
US (2) US20190328848A1 (zh)
EP (2) EP3556386A4 (zh)
JP (2) JP7182793B2 (zh)
CN (2) CN110167582A (zh)
CA (2) CA3047171A1 (zh)
TW (4) TW201822797A (zh)
WO (3) WO2018107695A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI734798B (zh) 2016-12-15 2021-08-01 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療肺纖維化的方法
CN111344004A (zh) 2017-06-19 2020-06-26 泰伦基国际有限公司 一种调控glp-1/glp-1r 的方法和药物
TW201904990A (zh) 2017-06-23 2019-02-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN113456579B (zh) * 2021-07-12 2023-04-25 南开大学 具有双靶点的hdac抑制剂的纳米胶束-水凝胶制剂在治疗急性肾损伤药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CN101573134A (zh) * 2006-08-28 2009-11-04 欧姆尼治疗有限公司 抗感染候选药物
WO2013049697A1 (en) * 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
CN87104683A (zh) * 1986-05-15 1988-12-21 埃默里大学 改善血纤维蛋白溶解作用的组合物
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
MXPA04007585A (es) * 2002-02-06 2005-09-20 N Zyme Biotec Gmbh Metodo para la produccion de proteinas recombinantes en microorganismos.
EP1509236A4 (en) * 2002-05-13 2008-07-30 Children S Hospital Los Angele TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS
DE60306547T2 (de) * 2002-12-10 2007-06-28 Wyeth Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen-aktivator
CA2577782A1 (en) * 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as pai-1 inhibitors
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
JP5736597B2 (ja) * 2009-05-26 2015-06-17 ウニベルシダド・デ・サラマンカ 急性腎不全又は急性腎不全発症リスクのマーカーとしての尿中ｇｍ２活性化タンパク質
RU2564131C2 (ru) * 2009-07-10 2015-09-27 ТромбоДженикс НВ Варианты плазминогена и плазмина
CN102121023B (zh) * 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
BR112013017172A2 (pt) * 2011-01-05 2016-10-11 Thrombogenics Nv variantes de plasminogênio e plasmina
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
PE20160244A1 (es) * 2013-08-13 2016-05-10 Sanofi Sa Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos
PT3109320T (pt) * 2014-02-21 2019-06-06 Astellas Pharma Inc Novo anticorpo anti-pai-1 humano

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CN101573134A (zh) * 2006-08-28 2009-11-04 欧姆尼治疗有限公司 抗感染候选药物
WO2013049697A1 (en) * 2011-09-29 2013-04-04 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. RICHARD KITCHING 等: "Plasminogen and Plasminogen Activators Protect against Renal Injury in Crescentic Glomerulonephritis", 《J.EXP.MED》 *
ELIZABETH J FISHER等: "Displacement of Tissue Bound Plasminogen by Glucose: A Possible Mechanism in the Pathogenesis of Diabetic Nephropathy", 《ENDOCRINOLOGY AND METABOLISM》 *
庞新路，等: "《现代肾脏病学理论与应用》", 30 June 2013 *
张颖玮，等: "《肾脏病学现代基础与临床》", 30 April 2009 *
袁发焕，等: "《实用肾脏病临床诊疗学》", 30 June 2016 *

Also Published As

Publication number Publication date
EP3556386A1 (en) 2019-10-23
US20190328848A1 (en) 2019-10-31
JP7182793B2 (ja) 2022-12-05
JP7242057B2 (ja) 2023-03-20
WO2018107700A1 (zh) 2018-06-21
JP2020502134A (ja) 2020-01-23
TW201822793A (zh) 2018-07-01
TW202123962A (zh) 2021-07-01
CA3047170A1 (en) 2018-06-21
TW201822797A (zh) 2018-07-01
WO2018107695A1 (zh) 2018-06-21
CA3047171A1 (en) 2018-06-21
WO2018107699A1 (zh) 2018-06-21
JP2020502135A (ja) 2020-01-23
US20190343930A1 (en) 2019-11-14
TWI642441B (zh) 2018-12-01
CN110167582A (zh) 2019-08-23
EP3556388A1 (en) 2019-10-23
TW201822794A (zh) 2018-07-01
EP3556386A4 (en) 2020-07-08
EP3556388A4 (en) 2020-07-08
TWI661838B (zh) 2019-06-11

Similar Documents

Publication Publication Date Title
TWI750189B (zh) 一種治療冠狀動脈粥樣硬化及其併發症的方法
CN108778307A (zh) 一种预防和治疗糖尿病肾病的方法
CN110366427A (zh) 一种预防和治疗病理性肾组织损伤的方法
CN110139668A (zh) 一种预防和治疗肝纤维化的方法
TW201722470A (zh) 一種預防和治療肝組織損傷及其相關病症的方法
CN108210895A (zh) 预防动脉粥样硬化及其并发症的药物及其用途
CN108463236A (zh) 一种预防或治疗放射性和化学性损伤的方法
CN108210894A (zh) 预防和治疗病理性肾组织损伤的药物及其用途
CN106890324A (zh) 一种预防和治疗糖尿病肾病的方法
CN108210909A (zh) 预防和治疗脂质肾损伤的药物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination